<DOC>
	<DOCNO>NCT00887926</DOCNO>
	<brief_summary>The purpose study determine IMC-EB10 safe patient leukemia , also determine best dose IMC-EB10 give patient .</brief_summary>
	<brief_title>Study EB10 Patients With Leukemia</brief_title>
	<detailed_description>The purpose study define maximum tolerate dose ( MTD ) pharmacokinetic ( PK ) profile anti-FLT3 monoclonal antibody IMC-EB10 , administer weekly patient AML fail achieve complete remission standard induction regimen , relapse response previous antileukemia therapy , eligible potentially curative approve salvage option .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . The patient acute myeloid leukemia bone marrow blood relapse without prior complete remission 2 . The patient regard candidate potentially curative , high priority treatment acute myeloid leukemia 3 . The patient resolution clinically significant toxic effect prior antitumor therapy studyspecific clinical laboratory parameter specify entry criterion 4 . The patient major surgery , open biopsy , significant injury , and/or prior antitumor therapy ( except antileukemia therapy ) within 21 day prior first infusion IMCEB10 5 . The patient performance status 0 , 1 , 2 study entry . 6 . The patient age 18 year old 7 . The patient life expectancy &gt; 3 month 8 . The patient adequate liver kidney function , define entry criterion 9 . The patient use effective contraception ( per institutional standard ) , procreative potential exist 10 . The patient able give write informed consent 11 . The patient willing able comply study procedure , schedule visit , treatment plan 1 . The patient prior allogenic autologous stem cell transplant within &lt; 3 month first infusion IMCEB10 2 . The patient organ transplant ( nonhematologic ) within 3 year study entry 3 . The patient active central nervous system leukemia 4 . The patient extramedullary disease without peripheral/and bone marrow involvement 5 . The patient diseasefree previous concurrent malignancy period â‰¤ 1 year . A patient basal cell carcinoma carcinoma situ cervix exclude study 6 . The patient currently receive antileukemia therapy . Concurrent treatment hydroxyurea permit 7 . The patient uncontrolled intercurrent illness specify study entry criterion 8 . The patient receive chronic steroid immunosuppressive medication . Occasional use steroidcontaining medication , eg , asthma exacerbation skin lesion , permit 9 . The patient receive fulldose heparin ( include low molecular weight heparin ) warfarin . ( The patient permit use lowdose warfarin maintain patency preexisting , permanent , indwell I.V . catheter . ) 10 . The patient pregnant ( confirm urine serum pregnancy test ) breast feed 11 . The patient receive treatment monoclonal antibody within 6 week prior first infusion IMCEB10 12 . The patient history clinically significant allergic reaction monoclonal antibody therapeutic protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>